Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Ren Fail. 2023;45(2):2263581. doi: 10.1080/0886022X.2023.2263581. Epub 2023 Oct 2.
The hematopoietic stem cell transplantation (HSCT) is performed for various hematological diseases. Chronic kidney disease (CKD) occurs relatively often after HSCT. Anemia after HSCT may be due to CKD and/or other reasons. The aim of this study is to assess the prevalence of anemia and its possible relationship to the presence of CKD in patients at least 3 months after HSCT. The study included 156 patients who underwent allogeneic HSCT treatment in our center in the years 1998 to 2021 due to different hematologic pathologies (acute myeloid leukemia, acute lymphoblastic leukemia, lymphoma, and others). Anemia was diagnosed in 13% of women and 35% of men. Anemia was most common in people after HSCT due to a history of acute myeloid leukemia (55% women, 30% men). In 56% of women and 17% of men, anemia was associated with chronic kidney disease. In patients with anemia, age was related to the eGFR (r = -0.39, < 0.001), in patients without anemia age was negatively related to eGFR (r = -0.56, < 0.001), and hemoglobin was positively related to platelet count ( = 0.62, < 0.001). Concluding, anemia, was relatively common in CKD after HSCT. In CKD, in particular with coexistent anemia, nephrology referral is to be taken into account to optimize therapy, including nephroprotection.
造血干细胞移植（HSCT）用于治疗各种血液疾病。慢性肾脏病（CKD）在 HSCT 后相对常见。HSCT 后贫血可能是由于 CKD 和/或其他原因引起的。本研究旨在评估至少在 HSCT 后 3 个月的患者中贫血的患病率及其与 CKD 存在的可能关系。该研究纳入了 1998 年至 2021 年在我们中心因不同血液病理学（急性髓系白血病、急性淋巴细胞白血病、淋巴瘤等）接受异基因 HSCT 治疗的 156 例患者。13%的女性和 35%的男性被诊断为贫血。HSCT 后因急性髓系白血病（女性 55%，男性 30%）而导致的贫血最为常见。在 56%的女性和 17%的男性中，贫血与慢性肾脏病相关。在贫血患者中，年龄与 eGFR 相关（r = -0.39， < 0.001），在无贫血患者中，年龄与 eGFR 呈负相关（r = -0.56， < 0.001），且血红蛋白与血小板计数呈正相关（r = 0.62， < 0.001）。结论，HSCT 后 CKD 贫血较为常见。在 CKD 中，特别是合并贫血时，应考虑转至肾病科以优化治疗，包括肾保护。
